NYSE:ASPNChemicals
Why Aspen Aerogels (ASPN) Is Down 13.3% After Impairment-Driven Loss And Strategic Review News
In February 2026, Aspen Aerogels reported fourth-quarter 2025 sales of US$41.34 million versus US$123.09 million a year earlier, swung to a net loss of US$72.91 million, recorded an impairment charge on property, plant and equipment, and launched a broad review of options for its business and capital structure.
An important insight is that management characterizes this strategic review as coming from a position of financial strength and operational progress, even as the company posts a...